Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference By Investing.com

Rockville, Maryland and Suzhou, China, December 26, 2024 /PRNewswire/ — Ascension Pharma (6855.HK), a global biopharmaceutical company engaged in the discovery, development and commercialization of therapeutics to address the global unmet medical need primarily for malignant tumors, today announced that its Chairman and CEO, Dr. Dagon Yangaccepted an invitation to make a presentation on the company’s progress and prospects within the framework of its global patient-focused innovation strategy, in 1:15 pm, January 16, 2025Pacific Time (5:15 AM, January 17, 2025, Beijing time) at the forty-third annual session JP Morgan Healthcare Conference.

Annual JP Morgan Healthcare Conference It is the largest and most informative event for the global pharmaceutical industry and investment community. This year the conference will be held in San Francisco, California, USon January 13-16, 2025.

time:

January 16, 2025; 1:15-1:40 PM PT
(January 17, 2025; 5:15-5:40 AM, Beijing time)

speaker:

doctor. Dagon YangChairman and CEO of the company Ascension Pharma

You can join the conference and listen to the live broadcast of the speech online at:
https://jpmorgan.metameetings.net/events/healthcare25/sessions/58522-ascentage-pharma-group-international/webcast?gpu_only=true&kiosk=true

on Ascension Pharma

Ascension Pharma (6855.HK) is a global integrated biopharmaceutical company engaged in the discovery, development and commercialization of therapeutics to address global unmet medical needs primarily in malignancies. on October 28, 2019, Ascension Pharma It is listed on the main panel of Hong Kong Stock Exchange Limited With stock code 6855.HK.

The company has built a rich pipeline of innovative drug candidates that includes novel, highly potent Bcl-2 inhibitors and Bcl-2/Bcl-xL duals, as well as candidates targeting the IAP and MDM2-p53 pathways and next-generation TKIs. Ascension Pharma It is also the only company in the world with active clinical programs targeting the three known classes of master apoptosis regulators. The company has conducted more than 40 clinical trials in the United States, Australia, Europeand Chinaincluding 13 registrational studies (completed/ongoing/planned).

Olverembatinib, the company’s first lead asset developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product in Chinahas previously been awarded Priority Review Designations and Breakthrough Therapy Designations China National Center for Drug Evaluation (CDE). medical (TASE:) Product Management (NMPA). So far, the drug has been listed on China’s National Reimbursement Drug List (NRDL). Furthermore, olverimpatinib has been granted Orphan Drug Designations (ODDs) and Fast Track Designation (FTD) by the US Food and Drug Administration. US Food and Drug AdministrationAnd orphan designation by the European Medicines Agency in the European Union.

yet, Ascension Pharma He got a total of 16 ODD from US Food and Drug Administration And one orphan designation from the European Union’s European Medicines Agency for four of the company’s investigational drug candidates. Leveraging its strong capabilities in research and development, Ascension Pharma It has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with many leading biotechnology and pharmaceutical companies such as Takeda and AstraZeneca (NASDAQ:), Merck (Ns:), Pfizer (NYSE:) and Innovent; And R&D relationships with leading research institutions such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and University of Michigan.

The company has built a talented team with a wealth of global experience in discovering and developing innovative medicines and fully operational manufacturing, sales and marketing teams. One pivotal goal Ascension Pharma It is to continuously enhance its research and development capabilities and accelerate its clinical development programs, in order to achieve its mission of meeting unmet clinical needs in China And all over the world to the benefit of more patients.

Forward-looking statements

The forward-looking statements in this article relate only to events or information as of the date the statements in this article are made. Except as required by law, Ascension Pharma The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date the statements are made or to reflect the occurrence of unanticipated events. You should read this entire article with the understanding that our actual results or performance in the future may be materially different from what we anticipate. In this article, statements or references are made to our intentions and expectations or those of any of our directors or our company as of the date of this article. Any of these intentions and expectations may change in light of future developments.